The availability of large, diverse datasets (“big data”) in the past 5 - 10 years, coupled with the exponential growth in computing power, increasingly sophisticated algorithms and major advances in experimental techniques for structural biology have firmly propelled artificial intelligence (“AI”) into drug discovery ("DD"). A variety of machine learning (“ML”) tools are now available across all stages of DD and development. This has led to the emergence of many AI-driven tech players looking to ....
21 Feb 2019
Early adoption of AI in drug design and beyond
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Early adoption of AI in drug design and beyond
Evotec SE (EVT:WBO) | 0 0 0.7% | Mkt Cap: 2,149m
- Published:
21 Feb 2019 -
Author:
Brigitte de Lima, PHD CFA -
Pages:
27
The availability of large, diverse datasets (“big data”) in the past 5 - 10 years, coupled with the exponential growth in computing power, increasingly sophisticated algorithms and major advances in experimental techniques for structural biology have firmly propelled artificial intelligence (“AI”) into drug discovery ("DD"). A variety of machine learning (“ML”) tools are now available across all stages of DD and development. This has led to the emergence of many AI-driven tech players looking to ....